Monopar Therapeutics Inc
MNPR57.750USD
+0.870+1.53%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
384.78MMarket Cap
LossP/E TTM
More Details of Monopar Therapeutics Inc Company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Monopar Therapeutics Inc Info
Ticker SymbolMNPR
Company nameMonopar Therapeutics Inc
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Number of employees16
Security typeOrdinary Share
Fiscal year-endDec 19
Address1000 Skokie Blvd Ste 350
CityWILMETTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60091-1146
Phone18473880349
Websitehttps://www.monopartx.com/
Ticker SymbolMNPR
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Company Executives of Monopar Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Feb 2
Updated: Mon, Feb 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Other
48.28%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Other
48.28%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
28.96%
Hedge Fund
19.01%
Corporation
14.94%
Investment Advisor
10.84%
Venture Capital
9.00%
Individual Investor
6.75%
Research Firm
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%
Other
10.12%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
123
4.56M
68.20%
+926.42K
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
1.29M
19.26%
+115.00K
+9.81%
Sep 30, 2025
Adage Capital Management, L.P.
659.20K
9.86%
+60.00K
+10.01%
Sep 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.14%
--
--
Apr 04, 2025
RA Capital Management, LP
511.21K
7.65%
--
--
Sep 30, 2025
AstraZeneca PLC
387.33K
5.8%
+387.33K
--
Oct 23, 2024
The Vanguard Group, Inc.
208.22K
3.12%
+121.73K
+140.75%
Sep 30, 2025
Wellington Management Company, LLP
231.46K
3.46%
+231.46K
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
182.63K
2.73%
-1.34K
-0.73%
Sep 30, 2025
Deerfield Management Company, L.P.
159.76K
2.39%
+159.76K
--
Sep 30, 2025
Saturn V Capital Management LP
155.37K
2.33%
+155.37K
--
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Date
Ex-dividend Date
Type
Ratio
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
